Xencor (NASDAQ:XNCR) Stock Price Down 3.9% – Time to Sell?

Xencor, Inc. (NASDAQ:XNCR) shares traded down 3.9% during trading on Friday . The company traded as low as $19.70 and last traded at $19.66. 67,569 shares were traded during mid-day trading, a decline of 87% from the average session volume of 537,709 shares. The stock had previously closed at $20.46.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Wells Fargo & Company began coverage on Xencor in a report on Thursday, December 12th. They set an “overweight” rating and a $37.00 target price on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Wedbush reissued an “outperform” rating and set a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. Royal Bank of Canada upped their price target on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, September 26th. Finally, JPMorgan Chase & Co. lifted their target price on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $34.88.

Xencor Stock Performance

The firm’s fifty day moving average is $23.69 and its 200 day moving average is $21.05. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -6.12 and a beta of 0.72. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. During the same period in the previous year, the company posted ($0.40) EPS. Xencor’s revenue was down 81.9% on a year-over-year basis. On average, analysts predict that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Insider Activity at Xencor

In other Xencor news, Director Alan Bruce Montgomery sold 13,301 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $27.03, for a total transaction of $359,526.03. Following the transaction, the director now owns 9,140 shares in the company, valued at $247,054.20. This trade represents a 59.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Bassil I. Dahiyat sold 3,366 shares of Xencor stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total transaction of $80,851.32. Following the completion of the transaction, the chief executive officer now directly owns 352,615 shares in the company, valued at approximately $8,469,812.30. This represents a 0.95 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 136,050 shares of company stock valued at $3,277,609. 5.23% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of XNCR. Quarry LP bought a new stake in shares of Xencor in the second quarter valued at approximately $36,000. GAMMA Investing LLC boosted its holdings in Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 508 shares during the period. KBC Group NV boosted its holdings in Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 1,213 shares during the period. XTX Topco Ltd acquired a new stake in Xencor in the 2nd quarter worth $196,000. Finally, Rockefeller Capital Management L.P. bought a new position in shares of Xencor during the 3rd quarter worth about $205,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.